The Northern Institute for Cancer Research (NICR) is a research institute consisting of a dedicated team of over 200 clinicians and scientists within the Faculty of Medical Sciences at Newcastle University, UK. The Faculty, one of three in the University, includes Biosciences, Dentistry and Medical Education, in addition to the traditional medical disciplines. It has focused its core research activity at the basic science/clinical interface into eight Research Institutes that contain internationally strong research in ageing, genetics, stem cells, cancer, health and society, biosciences, cellular medicine and neurosciences. In 2009 the NICR became Cancer Research UK's Newcastle Cancer Centre, a centre of excellence in Cancer, as part of a Cancer Research UK driven initiative. In the most recent Research Excellence Framework (REF 2014) assessment, 84% of research at the NICR was classed as world leading or internationally excellent. Within this HEFCE-coordinated external review process, Newcastle University was ranked 16th (out of 154) in the UK in terms of research power.
The NICR undertakes the bench to bedside development and trialling of anti-cancer drugs. It is a multidisciplinary translational research institute whose mission is to develop and evaluate improved therapies for human cancer. The NICR has programme grants from Cancer Research UK and the Leukaemia Research Fund, and is a Cancer Research UK Key Centre for early clinical trials. The NICR Paediatric Oncology & Haematology group has established itself as one of Europe's strongest translational research teams with a specific focus both on leukaemia & lymphoma and on cancers in children. The Newcastle group continue to act as the Children's Cancer and Leukaemia Group (CCLG) UK centre for conducting clinical pharmacology studies in paediatric oncology, with continued investment in the opening of new clinical trials alongside the publication of completed studies leading to further optimisation of cancer treatment. The Newcastle Cancer Centre Pharmacology Group have over 15 years of experience of running clinical trials in adult and pediatric oncology settings, including early phase clinical trials (Phase I/II) and large randomized studies. These studies are either designed and initiated within the institute and sponsored through the Newcastle upon Tyne Hospitals NHS Foundation Trust or involve local patient recruitment as part of national multi-centre studies sponsored by Cancer Research UK or the Birmingham Cancer Research Clinical Trials Unit (CRCTU). In all cases patients our recruited in Newcastle and sample analysis is carried out in the Newcastle Cancer Centre Pharmacology Group, with our laboratory commonly acting as the national reference laboratory for both pharmacokinetic and biomarker sample analysis according to the principles of Good Clinical Laboratory Practice.